Recipharm and Enzymatica have signed a broadened contract for the manufacture of ColdZyme.
The agreement will involve an additional Recipharm production site in Pianezza, Italy, to support Enzymatica in increasing production volumes of ColdZyme to meet growing global demand. Both the facilities in Parets, Spain, and Pianezza, Italy, will be making additional investments to accommodate requirements moving forward.
“Signing this expanded agreement is a great example of the long-term partnerships we build with our customers. Not only are we committed to providing high quality services and ensuring we meet project requirements, but we invest to adapt in line with our customers’ needs. This really is a testimony to the strength of our relationship with Enzymatica,” says Kenth Berg, Vice President Business Management at Recipharm.
ColdZyme is one of Enzymatica’s first products and is intended to treat and alleviate common cold. The product has already been launched in about 30 countries across three continents.